FLT3 and acute myeloid leukemia: Approximately 20% to 30% of patients with acute myeloid leukemia carry activating mutations in fms related receptor tyrosine kinase 3 (FLT3), particularly the FLT3-ITD mutation, which is a critical target for therapy.